natgillin/translations-raw huggingface dataset:
A combination comprising an acid addition salt according to claim 1 and one or more other therapeutic agent or treatment. 
Kiselinska adicijska sol prema zahtjevu 1, koja je sol dobivena s L-mliječnom kiselinom.
A micelle or Virus-Like-Particle (VLP) comprising an RSV F protein according to claim 1 or 2. 
RSV F protein prema zahtjevu 1, naznačen time što RSV F proteinu nedostaje N-terminalni signalni peptid.
The herbicidal composition according to claim 4, wherein the inorganic salt is a phosphate. 
Herbicidni pripravak u skladu s patentnim zahtjevom 5, naznačen time, da je neorganska sol fosfat.
Preparative HPLC of the three components (column: 2 x Lichrospher Si60, 5 µm, 250 x 21.20 mm, mobile phase: hexane: isopropanol (97:3), UV 254 nm; flow: 10 ml min-1) at 300 mg loading followed by concentration of the fractions of interest under vacuum gave the pure Mosher's ester derivatives Peak 1 (3.89 g, 46.5%) Peak 2 (2.78 g, 33%) 
Preparativna HPLC tri sastojka (kolona: 2 x Lichrospher Si60, 5 um, 250 x 21.20 mm, mobilna faza: heksan: izopropanol (97:3), UV 254 nm; protok: 10 ml min") uz punjenje od 300 mg i neposredno nakon koje slijedi koncentriranje poželjnih frakcija uz vakuum, daje čiste derivate Mosher-ovog estera. Peak 1 (3.89 g, 46.5%) Peak 2 (2.78 g, 33%)
The composition of Claim 2, wherein the baclofen is at least about 55 mole percent R-baclofen, at least about 60 mole percent R-baclofen, at least about 65 mole percent R-baclofen, at least about 70 mole percent R-baclofen, at least about 75 mole percent R-baclofen, at least about 80 mole percent R-baclofen, at least about 85 mole percent R-baclofen, at least about 90 mole percent R-baclofen or at least about 99 mole percent R-baclofen. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što je baklofen u najmanju ruku otprilike 80 molarnih postotaka R-baklofena, u najmanju ruku otprilike 85 molarnih postotaka R-baklofena, u najmanju ruku otprilike 90 molarnih postotaka R-baklofena, u najmanju ruku otprilike 95 molarnih postotaka R-baklofena ili u najmanju ruku otprilike 99 molarnih postotaka R-baklofena.
The mechanism according to claim 1, wherein said first and second helixes are configured as a bidirectional screw thread. 
Mehanizam prema zahtjevu 1, naznačen time da se navedeni izduženi dijelovi pružaju dalje od prvog zupčanika.
In still another particular embodiment, a method is provided for producing ADAMTS13 in a continuous cell culture, the method comprising (a) culturing non-anchorage dependent cells mammalian cells expressing recombinant ADAMTS13 protein in a continuous cell culture system, where the cell culture system comprises a macroporous microcarrier cell retention device having a cell retention rate of less than 90%, and has a dilution rate (D) between 0.1 and 1.0 d-1 and a cell density of less than 1 X 107 cell/mL; and (b) recovering the ADAMTS13 from medium removed from the cell culture system. 
Postupak proizvodnje polipeptida u kontinuiranoj staničnoj kulturi, navedeni postupak sadrži: (a) kultiviranje stanica sisavaca koje eksprimiraju polipeptid u kontinuiranom sustavu stanične kulture, pri čemu navedeni sustav stanične kulture sadrži uređaj za zadržavanje stanica 1 ima stupanj razrjeđenja (D) od manje od 2 d"' i gustoću stanica od manje od 2 X 10 " stanica/mL; i (b) obnavljanje navedenog polipeptida iz medija uklonjenog iz navedenog sustava stanične kulture; pri čemu su navedene stanice genetički modificirane kako bi eksprimirale sličan disintegrinu i metalopeptidaza s trombospondinom tip 1 motiv 13 (ADAMTS13) protein.
The compound for use of claim 1, wherein the disease or disorder is breast cancer. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak jetre.
A composition according to claim 5, wherein the composition is administered orally, as a solution, tablet, sustained release capsule, enteric-coated capsule or syrup. 
Pripravak sukladno zahtjevu 3, naznačen time, da se pripravak daje oralno, kao otopina, tableta, kapsula sa produženim otpuštanjem, enterički obložena kapsula ili sirup.
Process step c) according to claim 7 for the manufacture of compounds of general formula I, characterized in that epoxides of general formula VI optionally in its enantiomerically pure form are reacted with compounds of general formula R5-Met 
dijastereoizomera. 10. Korak c) postupka prema zahtjevu 7 koji je za proizvodnju spojeva opće formule I, naznačen time da epoksidi s općom formulom VI proizvoljno u njihovom enantiomerno čistom obliku
An example of the surface treatment of a composite dental material is described in the following. 
Primjer tretmana površine kompozitnog dentalnog materijala je kako je dalje opisano.
the amount of protein present in the etanercept-containing protein mixture obtained from purification of step 2 is at least about 80 wt.% of the amount of the etanercept-based protein mixture present in the harvest cell culture fluid obtained in step 1. 
HR P20180182 T1 pri čemu: (i) - količina proteina prisutnog u mješavini proteina koja sadrži etanercept dobiven pročišćavanjem iz koraka 2 je najmanje oko 80 tež. % količine mješavine proteina na osnovi etanercepta prisutnog u tekućini prikupljenih kultura stanica dobivenom u koraku 1.
The pipeline system according to claim 9, wherein the first and/or second base body are respectively implemented as elbow fittings. 
Sustav cijevi u skladu s patentnim zahtjevom 10, naznačen time što se prvo i/ili drugo osnovno tijelo (21) odgovarajuće ugrađuje kao kutne dijelove.
The pharmaceutical composition of Claim 12 wherein the one or more other therapeutic agents is selected from HCV NS3 protease inhibitors, and HCV NS5B nucleoside and non-nucleoside polymerase inhibitors. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 12, naznačen time, da jedan ili više drugih terapijskih sredstava je odabrano od inhibitora proteaze HCV NS3 i HCV NS5B nukleozidnog ili nenukleozidnog inhibitora polimeraze.
The solid form of claim 6, wherein the form is crystalline Compound I-1 anhydrous free base, and the solid form is characterized by one or more peaks expressed in 2-theta ± 0.2 at 9.9, 12.8, 15.4, 17.0, 23.1, 27.8, 29.0, and 30.1 degrees in an X-Ray powder diffraction pattern obtained using Cu K alpha radiation. 
Čvrsti oblik u skladu s patentnim zahtjevom 6, pri čemu je oblik bezvodna baza kristalnog spoja I-1, naznačen time, da čvrsti oblik karakterizira jedan ili više vrhova izraženih u 2-theta +/- 0,2 u 9,9, 12,8, 15,4, 17,0, 23,1, 27,8, 29,0 i 30,1 stupnjeva u difrakcijskom dijagramu rendgenskih zraka dobivenom korištenjem K-alfa zračenja Cu.
The dose and frequency of administration of the medicament of the present invention are not particularly limited, and they may be appropriately chosen depending on conditions such as a purpose of preventive and/or therapeutic treatment, a type of a disease, the body weight or age of a patient, severity of a disease and the like. 
Doza and učestalost primjeni lijeka prema ovom izumu nisu osobito ograničeni, a može ih se prikladno odabrati ovisno o uvjetima, poput svrhe preventivnog i/ili terapijskog liječenja, tipa bolesti, tjelesne težine ili dobi pacijenta, težina bolesti 1 slično.
each one of said lower end portions of said arms comprises a protuberant formation configured to bear against and prop said lower end portions of said arms against an outer surface of said fixed support structure. 
Sustav dizalica (10, 100) sukladno zahtjevu 2, naznačen time da svaki od prvih ekstremiteta (22, 122) sadrži formaciju izbočenja konfiguriranu tako da nosi i učvršćuje odgovarajuće krakove (20,120) na vanjsku površinu fiksne potporne strukture (16,116).
Use of (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the preparation of a medicament, for simultaneous, concurrent, separate or sequential use in combination with (a) a PDE4 inhibitor for the treatment of a respiratory disease which responds to M3 antagonism in a patient. 
Pakiranje, naznačeno time, da se sastoji od (b) antagonista M3 muskarinskih receptora kako je definiran u patentnom zahtjevu 1 ili 2 i (a) kortikosteroida kako je definiran u bilo kojem od patentnih zahtjeva 1 i 3 do 6 za istovremenu, istodobnu, odijeljenu i uzastopnu uporabu za liječenje ljudi i životinja koji pate ili su podložni dišnim bolestima kako je definirano u patentnom zahtjevu 10 ili 11.
An apparatus according to claim 1, wherein the first release device is configured to vaporize or gasify the first substance associated with the first cartridge. An apparatus according to claim 4, further comprising: 
E-cigareta (100) sukladno patentnom zahtjevu 1, naznačena time što je uređaj za prvo oslobađanje (118) konfiguriran za isparavanje ili uplinjavanje prve tvari povezane s prvim spremnikom (114).
Medicament or pharmaceutical composition according to claim 8, wherein said arthritic condition is rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis. 
Smjesa, lijek ili farmaceutski pripravak za upotrebu prema bilo kojem zahtjevu od 1 do 5, naznačeni time da je navedeno artritično stanje reumatoidni artritis, ankilozantni spondilitis, juvenilni idiopatski artritis i psorijatični artritis.
z is selected from 1, 2, and 3; 
z se bira između 1, 2 i 3;
Elastomer materials are well known and have innumerable uses. A particular use is for the manufacture of closures for pharmaceutical vials and plungers for hypodermic syringes. 
Ovaj izum se odnosi na novi proizvod koji obuhvaća zatvarače za farmaceutske bočice i klipove za potkožne šprice, i na postupak za njihovu upotrebu.
Histamine H3 Receptor Binding 
Vezivanje za histaminski H3 receptor
A composition comprising the isolated antibody or antigen-binding portion thereof of claim 1 and a pharmaceutically acceptable carrier. 
Supstanca koja ukjljučuje izolirano antitijelo ili njegov dio koji veže antigen sukladno patentnom zahtjevu 8 i farmaceutski prihvatljiv nosač.
A method according to claim 13, wherein the rudder propeller devices in all provide at least a half of the total propulsion power of the watercraft. 
Plovilo prema zahtjevu 10. naznačeno time da su kormilo-propeler-uređaji (4) u cijelosti odgovaraju najmanje polovici ukupnog učinka plovila.
The method of claim 6, wherein the isolating step comprises isolating scaffold molecules binding to the specific target and testing the isolated scaffold molecules for binding affinity to the specific target, wherein optionally: 
Postupak prema patentnom zahtjevu 6, pri čemu korak izoliranja sadrži izoliranje platformskih molekula koje se vežu na određenu metu 1 testiranje izoliranih platformskih molekula za afinitet vezivanja na određenu metu, pri čemu, opcionalno:
Use according to any one of the preceding claims, characterized in that the calcium carbonate of said carbonate-comprising material is a precipitated calcium carbonate (PCC), a natural ground calcium carbonate (NGCC), a surface-reacted calcium carbonate (SRCC), or a mixture thereof. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da je navedeni materijal koji sadrži kalcijev karbonat istaloženi kalcijev karbonat (PCC), prirodna ruda kalcijevog karbonata (NGCC), površinski-izreagirani kalcijev karbonat (SRCC) ili njihova smjesa.
In the same way, the method according to the invention can comprise the steps of using strips of flexible material which comprise a fabric, and of aligning the threads of the fabric in the transverse direction of the core elements. 
Postupak u skladu s jednim od patentnih zahtjeva 8 do 11, naznačen time što sadržava korake upotrebe trake od fleksibilnog materijala, koji materijal sadržava proizvod od tekstila odnosno tkani proizvod 1 vlakna koja su postavljena u smjeru koji stoji poprijeko na središnje elemente.
The method of claim 2, wherein the pattern of the first IoT device comprises a pattern of attribute-value pairs of the schema of the first IoT device. 
Postupak prema Zahtjevu 2, gdje obrazac prvog IoT uređaja sadrži obrazac parova atribut-vrijednost sheme prvog IoT uređaja.
The aqueous pharmaceutical suspension according to claim 7, wherein the xylitol, sorbitol or sorbitol solution, or maltitol solution is, by weight/volume (g/100 mL), 0% to about 20%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što ksilitol, sorbitol ili otopina sorbitola ili otopina maltitola iznosi, težinski/volumno (g/100 ml), 0 % do otprilike 20 %.
Q is a leaving group selected from the group comprising a halogen atom, a mesylate group (CH3SO3-) and a tosylate group (p-MePhSO3-), to give a tricyclic indazole derivative of general formula (I). 
Q je izlazna skupina odabrana iz skupine koju čine atom halogena, mesilat-skupina (CH32SO3) 1 tosilat-skupina (p- MePhSO;), za dobivanje tricikličkog derivata indazola opće formule (1). 12.
The method of claim 7, wherein the Mucopolysaccharidosis is MPS I, II, IIIA, IIIB, IIIC, IIID, IVA, IVB, VI, or VII. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što je mukopolisaharidoza MPS I, II, IIIA, IIIB, IIC, HID, IVA, IVEB, VI ili VII.
A compound of formula (I): or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: 
Spoj s formulom (I): [image] ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer, naznačen time da: X je C=O ili CH2;
The preparations may also contain buffer salts, flavouring, colouring and/or sweetening agents (e.g. mannitol) as appropriate. 
Pripravci prema prigodi također mogu sadržavati puferske soli, arome, boje i/ili sladila (primjerice manitol).
The samples are transferred to eppendorf tubes and spun at 10000 G and 37° C. for 10 minutes. 
Uzorci su preneseni u eppendorf-tube 1 centrifugirani na 10000 G na 37 "C tijekom 10 min.
A pharmaceutical composition comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to 400 µg (plus/minus 10%) aclidinium bromide for use by inhalation in the treatment of asthma. 
PATENTNI ZAHTJEVI Farmaceutski pripravak koji sadrži aklidinij u obliku suhog praha farmaceutski prihvatljive soli u smjesi s farmaceutski prihvatljivim nosačem suhog praha, pružajući odmjerenu nominalnu dozu aklidinija jednaku 400 ug (plus/minus 10 %) aklidinijevog bromida za primjenu inhalacijom u liječenju kronične opstruktivne plućne bolesti.
The combination for use according to claim 13, wherein the additional therapeutic agent is an atypical antipsychotic. 
Kombinacija za uporabu prema zahtjevu 13, naznačena time da je dodatno terapeutsko sredstvo atipični antipsihotik.
The method for producing a nicotine-containing granulate according to claim 13, wherein the excipient used in step (a) is selected from the group consisting of saccharose, lactose, glucose, fructose, xylose, starch, sorbit, mannit, xylit, sugar alcohols, cellulose, calcium carbonate, calcium hydrogenphosphate, maltodextrin, and combinations thereof. 
Postupak dobivanja granulata koji sadrži nikotin u skladu s patentnim zahtjevom 7, naznačen time što se pomoćnu tvar upotrijebljenu u koraku (a) bira iz skupine koju čine saharoza, laktoza, glukoza, fruktoza, ksiloza, škrob, sorbitol, manitol, ksilitol, šećerni alkoholi, celuloza, kalcijev karbonat, kalcijev hidrogenfosfat, maltodekstrin, te njihove kombinacije.
A compound of formula I: wherein A is NH2; and B is H; or a pharmaceutically acceptable salt or hydrate thereof, for use in the inhibition of RNA viral polymerase in a subject, wherein the RNA viral polymerase is: 
Spoj formule I: [image] pri čemu A je NH2; i B je H; ili njegova farmaceutski prihvatljiva sol ili hidrat, namijenjen upotrebi u inhibiciji RNK viralne polimeraze kod subjekta, pri čemu je virusna RNK polimeraza:
ON represents an oligonucleotide comprising at least 4 nucleotides or nucleotide analogue building blocks, comprising the steps: 
ON predstavlja oligonukleotid koji obuhvaća najmanje 4 nukleotida ili građevne blokove nukleotidnih analoga, a koji obuhvaća korake:
The agonist for use according to claim 6, wherein said a adrenergic receptor agonist is for administration in a pharmacologically acceptable form selected from solutions, gels, lotions creams, ointments, foams, emulsions, microemulsions, milks, serums, aerosols, sprays, dispersions, microcapsules, vesicles and microparticles thereof, soaps, and cleansing bars. 
Agonist za uporabu u skladu sa zahtjevom 1, naznačen time što se agonist alfa adrenergijskog receptora primjenjuje u farmakološki prihvatljivom obliku odabranom od otopina, gelova, losiona, krema, masti, pjena, emulzija, mikroemulzija, mlijeka, seruma, aerosola, sprejeva, disperzija, mikrokapsula, njihovih mikročestica, sapuna, te pločica za čišćenje.
The pharmaceutical composition of embodiment 23, wherein the excipient is selected from the group consisting of mannitol, xylitol, sorbitol, maltol, maltitol, lactose, sucrose, maltose, and combinations thereof. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 12, naznačeno time da je ekscipijens odabran iz skupine koju čine manitol, ksilitol, sorbitol, maltol, maltitol, laktozu, saharozu, maltozu, i njihove kombinacije.
The pharmaceutical composition of claim 3, wherein the pharmaceutical composition is suitable for intravenous administration. 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 3, gdje farmaceutska kompozicija treba da se administrira intravenski.
The process of paragraph 12, wherein Compound 3 is prepared by a process selected from the group consisting of: and, wherein: 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što Spoj 3 se dobiva postupkom kojeg se bira iz skupine koju čine:
the antibody is suitable for administrating by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intraarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal; or 
Antitijelo prema patentnom zahtjevu 13, naznačeno time, što se dovodi u kontakt odnosno primjenjuje na najmanje jedan od načina koji je izabran iz grupe koju čine parenteralna, potkožna, intramuskularna, intravenozna, intraartikularna, intrabronhijalna, intraabdominalna, intrakapsularna, intrahrskavična, intrakavitalna, intrakomorna, intracerebelarna, intracerebroventrikularna, intrakolična, intracervikalna, intragastrična, intrahepatična, intramiokardna, intraostealna, intrapelvična, intraperikardijalna, intraperitonealna, intrapleuralna, intraprostatična, intrapulmonalna, intrarektalna, intrarenalna, intraretinalna, intraspinalna, intrasinovijalna, intratorakalna, intrauterina, intravezikularna, intralezijska, bolusna, vaginalna, rektalna, bukalna, sublingvalna, intranazalna i transdermalna primjena.
The method of item 63 or the compound, the polymorphic form, or the pharmaceutical composition for use according to item 66, or the use of item 66, wherein the eye disorder is uveitis, macular degeneration, glaucoma, diabetic macular edema, blepharitis, diabetic retinopathy, a disease or disorder of the corneal endothelium, post-surgical inflammation, dry eye, allergic conjunctivitis, or a form of conjunctivitis. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je poremećaj oka odabran od uveitisa, makularne degeneracije, glaukoma, dijabetičkog makularnog edema, blefaritisa, dijabetičke retinopatije, bolesti ili poremećaja endotela rožnice, postoperativna upala, sindrom suhog oka, alergijski konjunktivitis, te oblik konjunktivitis.
A pharmaceutical composition comprising: (a) a therapeutically effective amount of the isolated solid form of anamorelin monohydrochloride of claim 1 or 15; and (b) one or more pharmaceutically acceptable excipients. 
4. - Farmaceutski sastav koji sadrži: a) terapeutski efikasnu količinu anamorelin monohidroklorida prema patentnim zahtjevima 1, 2 ili 3; 1 b) jedan ili više farmaceutski prihvatljivih ekscipijenata.
The composition according to claim 7 which comprises flupentixol 2HCl corresponding to 0.5 mg free base and melitracen HCl corresponding to 10 mg free base. 
Oblik prema zahtjevu 7 koji sadrži flupentiksol 2HCI što odgovara 0.5 mg slobodne baze i melitracen HC] što odgovara 10 mg slobodne baze.
the bond represented by a dashed and solid line represents a bond selected from the group consisting of a single bond and a double bond with the proviso that the dashed and solid line can only be a double bond when n is 1; 
[image] i opcionalno, pritom se premještanje bromo skupine postiže uporabom sredstva koje je odabrano iz skupine koju čine: a-alkoksi supstituirani alkil-litijev agens, organomagnezijev reagens, natrijeva sol derivata alkila, i natrijeva sol derivata arilkarbamata.
The present invention also provide methods for enhancing the activity of glucocerebrosidase in a cell ex vivo using 5-(fluoromethyl)piperidine-3,4-diol, 5-(chloromethyl)piperidine-3,4-diol, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or any combination of two or more thereof. 
H F OH CH ili njegova farmaceutski prihvatljiva sol, ili bilo koja kombinacija dva ili više; za upotrebu u prevenciji i/ili liječenju poremećaja lizosomskog nakupljanja kod pacijenta s rizikom za razvoj ili dijagnozom istog.
Fatty acids: Fatty acids that are known to be used in media are Arachidonic Acid, Linoleic Acid, Oleic Acid, Lauric Acid, Myristic Acid, as well as Methyl-betaCyclodextrin, see e.g. 
-masne kiseline: Masne kiseline za koje se zna da se koriste u medijima za kulturu stanica su arahidonska kiselina, Hnoleinskakiselina, oleinska kiselina, laurinska kiselina, miristinska kiselina, kao i metil-betaciklodekstrin, vidi pr.
In another preferred embodiment of the pharmaceutical methods of the invention, the pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct is to be administered by continuous infusion for at least four weeks followed by a 2-week treatment-free interval. 
Konstrukt za uporabu prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što se farmaceutski pripravak koji sadrži CD19xCD3 konstrukt protutijela bispecifičnog jednostrukog lanca treba davati kontinuiranom infuzijom najmanje četiri tjedna nakon čega slijedi interval od 2 tjedna bez tretmana.
The lipid formulation of claim 4, wherein the therapeutic agent is an antisense, siRNA or ribozyme. 
Lipidni pripravak u skladu s patentnim zahtjevom 4, naznačen time, da je terapijsko sredstvo antisens, siRNA ili ribozim.
Following illumination, the samples were analysed by SPME-GC-MS. 
Nakon osvjetljavanja, uzorci su analizirani pomoću SPME-GC-MS.
Various coating compositions have been proposed, e.g., a petroleum solvent solution of a waxy film former and a fungicide (U.S. Pat. No. 4,006,259); a mixture of lard, tallow, and lecithin applied in molten state (U.S. Pat. No. 4,207,347); hydrogenated jojoba oil (U.S. Pat. no. 4,356,197); a salt of carboxylic acid and an alkyl amine (U.S. Pat. 
Predložene su različite smjese za oblaganje, npr. otopina naftnog otapala i sredstva za stvaranje voštanog filma i fungicida (US Pat. br. 4,006,259); smjesa svinjske masti, loja i lecitina koja se primjenjuje u rastopljenom stanju (US Pat. br. 4,207,347); hidrogenirano ulje jojobe (US Pat. br. 4,356,197); sol karbonske kiseline i alkil amina (US Pat. br.
Examples of soluble, non selective, non digestible polysaccharides are xanthan, tara, carrageenan, tragacanth, locust bean gum, agar, guar gum, arabic gum, carboxymethylcellulose, and pectin. 
Primjeri topljivih, neselektivnih, neprobavljivih polisaharida su ksantan, tara, karagenan, tragakant, rogačeva guma, guarova guma, arapska guma, karboksimetilceluloza i pektin.